nach oben

Erschienen in:

31.03.2017 | Original Paper

Providers’ Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study

verfasst von: W. David Lohr, Kyle B. Brothers, Deborah Winders Davis, Carla A. Rich, Lesa Ryan, Michael Smith, Michelle Stevenson, Yana Feygin, Charles Woods, John Myers, Gilbert C. Liu

Erschienen in: Community Mental Health Journal | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Fragmentation in behavioral and mental health care to children has resulted in suboptimal care and high rates of psychotropic medication use, especially antipsychotic medications (APM). A qualitative study, based on the Theory of Planned Behavior (TPB), aimed to better understand prescribing practices, barriers to optimal treatment, and potential interventions to safeguard the use of APM for children in Kentucky. The most common barrier to optimal care was access to mental health specialists. Social norms and pressure from families contribute to increased medication use. We identify promising interventions to safeguard the use of APM through the lens of the TPB.

Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Decision Making Processes, 50, 179–211.CrossRef

Almandil, N. B., Liu, Y., Murray, M. L., Besag, F. M., Aitchison, K. J., & Wong, I. C. (2013). Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: A systematic review and meta-analysis. Paediatric Drugs, 15(2), 139–150.CrossRef

American Academy of Child & Adolescent Psychiatry. (2009). Practice parameter on the use of psychotropic medication in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 48(9), 961–973. doi:10.1097/CHI.0b013e3181ae0a08.CrossRef

American Psychiatric Association. (2013). Choosing wisely: Five things physicians and patients should question Retrieved December 4, 2015, from http://www.choosingwisely.org/societies/american-psychiatric-association/.

Arango, C., Giraldez, M., Merchan-Naranjo, J., Baeza, I., Castro-Fornieles, J., Alda, J. A., et al. (2014). Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. Journal of the American Academy of Child & Adolescent Psychiatry, 53(11), 1179–1190. doi:10.1016/j.jaac.2014.08.009.CrossRef

Becker, E. R., Constantine, R. J., McPherson, M. A., & Jones, M. E. (2013). Antipsychotic polypharmacy prescribing patterns and costs in the Florida adult and child Medicaid populations. Journal of Health Care Finance, 40(1), 40–67.PubMed

Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70(10), 1067–1075.CrossRef

Carbon, M., Kapoor, S., Sheridan, E., Al-Jadiri, A., Azzo, S., Sarkaria, T., et al. (2015). Neuromotor adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 s-generation antipsychotics. Journal of the American Academy of Child & Adolescent Psychiatry, 54(9), 718–727. doi:10.1016/j.jaac.2015.06.015.CrossRef

Carpenter-Song, E., & Snell-Rood, C. (2016). The changing context of rural America: A call to examine the impact of social change on mental health and mental health care. Psychiatric Services, appips201600024. doi:10.1176/appi.ps.201600024.CrossRef

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: The Journal of the American Medical Association, 302(16), 1765–1773. doi:10.1001/jama.2009.1549.CrossRefPubMed

Crystal, S., Olfson, M., Huang, C., Pincus, H., & Gerhard, T. (2009). Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs, 28(5), w770–w781. doi:10.1377/hlthaff.28.5.w770.CrossRefPubMed

Davis, D. W., Smith, M. J., Feygin, Y., Myers, J., Lohr, D., Collins-Camargo, C., Williams, P. G., Jones, V. F. (2016). Medication prescribing to children insured by Kentucky Medicaid interim report December 2016. Unpublished data analysis. Pediatrics. University of Louisville. Louisville, KY.

De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26(3), 144–158. doi:10.1016/j.eurpsy.2010.09.011.CrossRefPubMed

dosReis, S., Yoon, Y., Rubin, D. M., Riddle, M. A., Noll, E., & Rothbard, A. (2011). Antipsychotic treatment among youth in foster care. Pediatrics, 128(6), e1459–e1466. doi:10.1542/peds.2010-2970.CrossRefPubMedPubMedCentral

Fairbrother, G. L., Emerson, H. P., & Partridge, L. (2007). How stable is medicaid coverage for children? Health Affairs, 26(2), 520–528. doi:10.1377/hlthaff.26.2.520.CrossRefPubMed

Findling, R., Drury, S., Jensen, P., & Rappaport, J. (2011). Practice parameter for the use of atypical antipsychotic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP). Washington, D.C.

Fraguas, D., Correll, C. U., Merchan-Naranjo, J., Rapado-Castro, M., Parellada, M., Moreno, C., et al. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology, 21(8), 621–645. doi:10.1016/j.euroneuro.2010.07.002.CrossRefPubMed

Friedman, R. M., & Kutash, K. (1992). Challenges for child and adolescent mental health. Health Affairs, 11(3), 125–136.CrossRef

Hilt, R. J., Romaire, M. A., McDonell, M. G., Sears, J. M., Krupski, A., Thompson, J. N., et al. (2013). The partnership access line: Evaluating a child psychiatry consult program in Washington State. JAMA Pediatrics, 167(2), 162–168.CrossRef

Hilt, R. J., Barclay, R. P., Bush, J., Stout, B., Anderson, N., & Wignall, J. R. (2015). A statewide child telepsychiatry consult system yields desired health system changes and savings. Telemedicine Journal and E-health: The Official Journal of the American Telemedicine Association, 21(7), 533–537. doi:10.1089/tmj.2014.0161.CrossRef

Hogan, M. F. (2003). The President’s New Freedom Commission: Recommendations to transform mental health care in America. Psychiatric Services, 54(11), 1467–1474. doi:10.1176/appi.ps.54.11.1467.CrossRefPubMed

Howie, L. D., Pastor, P. N., & Lukacs, S. L. (2014). Use of medication prescribed for emotional or behavioral difficulties among children aged 6–17 years in the United States, 2011–2012: NCHS data brief. Hyattsville, MD: National Center for Health Statistics.

Knapp, P., Chait, A., Pappadopulos, E., Crystal, S., & Jensen, P. S. (2012). Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management. Pediatrics, 129(6), e1562–e1576. doi:10.1542/peds.2010-1360.CrossRefPubMed

Lohr, W. D., Chowning, R. T., Stevenson, M. D., & Williams, P. G. (2015). Trends in atypical antipsychotics prescribed to children six years of age or less on Medicaid in Kentucky. Journal of Child and Adolescent Psychopharmacology, 25(5), 440–443. doi:10.1089/cap.2014.0057.CrossRefPubMedPubMedCentral

Medco Health Solutions. (2011). America’s state of mind Retrieved February 1, 2017, from http://apps.who.int/medicinedocs/documents/s19032en/s19032en.pdf.

Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., et al. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatric and Adolescent Medicine, 164(4), 344–351. doi:10.1001/archpediatrics.2010.48.CrossRef

Murphy, A. L., Gardner, D. M., Kisely, S., Cooke, C. A., Kutcher, S. P., & Hughes, J. (2015). System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents. Clinical Child Psychology and Psychiatry. doi:10.1177/1359104515617518.CrossRefPubMedPubMedCentral

Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010). Trends in antipsychotic drug use by very young, privately insured children. Journal of the American Academy of Child & Adolescent Psychiatry, 49(1), 13–23.

Olfson, M., Blanco, C., Liu, S. M., Wang, S., & Correll, C. U. (2012). National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry, 69(12), 1247–1256. doi:10.1001/archgenpsychiatry.2012.647.CrossRefPubMed

Olfson, M., Blanco, C., Wang, S., Laje, G., & Correll, C. U. (2014). National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry, 71(1), 81–90. doi:10.1001/jamapsychiatry.2013.3074.CrossRefPubMed

Pidano, A. E., & Honigfeld, L. (2012). Pediatric psychopharmacology: Context, model programs, and considerations for care. Psychiatric Services, 63(9), 929–934. doi:10.1176/appi.ps.201100318.CrossRefPubMed

Pope, C., & Mays, N. (2006). Qualitative research in health care. Malden, MA: Blackwell.CrossRef

Rosato, N. S., Correll, C. U., Pappadopulos, E., Chait, A., Crystal, S., & Jensen, P. S. (2012). Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics, 129(6), e1577–e1586. doi:10.1542/peds.2010-1361.CrossRef

Rubin, D. M., Kreider, A. R., Matone, M., Huang, Y. S., Feudtner, C., Ross, M. E., et al. (2015). Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatrics, 169(4), e150285. doi:10.1001/jamapediatrics.2015.0285.CrossRefPubMed

Sarvet, B., Gold, J., Bostic, J. Q., Masek, B. J., Prince, J. B., Jeffers-Terry, M., et al. (2010). Improving access to mental health care for children: The Massachusetts Child Psychiatry Access Project. Pediatrics, 126(6), 1191–1200.CrossRef

Seabury, S. A., Goldman, D. P., Kalsekar, I., Sheehan, J. J., Laubmeier, K., & Lakdawalla, D. N. (2014). Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. American Journal of Managed Care, 20(2), e52–e60.PubMed

Thomas, K. C., Ellis, A. R., Konrad, T. R., Holzer, C. E., & Morrissey, J. P. (2009). County-level estimates of mental health professional shortage in the United States. Psychiatric Services, 60(10), 1323–1328. doi:10.1176/ps.2009.60.10.1323.CrossRefPubMed

U.S. Department of Health and Human Services. (2013). The U.S. Health Workforce Chartbook Part 4: Behavioral and allied health. Rockville, MD: Health Resources and Services Administration (HRSA) and National Center for Health Workforce Analysis.

Zito, J. M., Safer, D. J., Zuckerman, I. H., Gardner, J. F., & Soeken, K. (2005). Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatric Services, 56(2), 157–163. doi:10.1176/appi.ps.56.2.157.CrossRefPubMed

Titel: Providers’ Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study
verfasst von: W. David Lohr
Kyle B. Brothers
Deborah Winders Davis
Carla A. Rich
Lesa Ryan
Michael Smith
Michelle Stevenson
Yana Feygin
Charles Woods
John Myers
Gilbert C. Liu
Publikationsdatum: 31.03.2017
Verlag: Springer US
Erschienen in: Community Mental Health Journal / Ausgabe 1/2018
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-017-0125-8

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Providers’ Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study

Abstract

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Demenzkranke durch Antipsychotika vielfach gefährdet

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

Update Psychiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Development of a Shared Decision Making Model in a Community Mental Health Center

Forensic Assertive Community Treatment in a Continuum of Care for Male Internees in Belgium: Results After 33 Months

Life Satisfaction and Psychological Status of Mothers with Disabled Children: A Descriptive Study

Supporting Shared Decision-making for Children’s Complex Behavioral Problems: Development and User Testing of an Option Grid™ Decision Aid

A Qualitative Study of Clinicians Experience with Rating of the Global Assessment of Functioning (GAF) Scale

The Italian Version of the Opening Minds Stigma Scale for Healthcare Providers: Validation and Study on a Sample of Bachelor Students

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Demenzkranke durch Antipsychotika vielfach gefährdet

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

Update Psychiatrie